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Abstract
Corticosteroids are adrenal hormones that play important physiologic roles including 
modulation of glucose metabolism, protein catabolism, alteration of calcium metabolism, 
regulation of bone turnover, suppression of immune system, and down-regulation of the 
inflammatory cascade. Because of their diverse effects, corticosteroids have been used 
therapeutically for treating a wide variety of auto-immune, rheumatologic, inflamma-
tory, neoplastic and infectious diseases. In the field of pulmonology, corticosteroids have 
been used for the treatment of reactive airway diseases (such as asthma and allergic bron-
chopulmonary aspergillosis), chronic obstructive pulmonary disease, sarcoidosis, colla-
gen vascular diseases (such as vasculitic disorders), eosinophilic pneumonitis, idiopathic 
interstitial pneumonias and infectious disorders (such as laryngotracheobronchitis). 
Different formulations of corticosteroids are commercially available including tablets, 
intravenous injections, intramuscular formulations and inhaled preparations. Long-term 
use of corticosteroids is often limited by their adverse effects, which include abnormal fat 
deposition, weight gain, diabetes mellitus, cataracts, glaucoma, osteoporosis, osteonecro-
sis, elevated risk of fractures, increased susceptibility to infections, proximal myopathy, 
depression, psychosis, adrenal atrophy with risk of Addisonian crisis, abdominal striae, 
acne vulgaris, delayed wound healing, easy bruising, electrolyte abnormalities and 
increased risk of peptic ulcer disease. As our understanding of corticosteroids advances, 
we may be able to identify individuals at higher risk of experiencing adverse effects.
Keywords: corticosteroids, glucocorticoids, respiratory diseases, airway disorders, 
asthma, chronic obstructive pulmonary disease, pneumonia, sarcoidosis
1. Introduction to corticosteroids
Corticosteroids are steroid hormones produced by the adrenal gland. Adrenal glands con-
stitute the endocrine system of the body and are a pair of pyramidal shaped glands located 
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just above the kidneys on either side of the body. Because of their location, they are also 
known as suprarenal glands and are perfused by suprarenal arteries, which arise on either 
side from renal arteries [1]. These endocrine glands are important as they secrete a number 
of hormones into the blood, which play a vital role in maintaining homeostasis. With respect 
to the structure of the adrenal glands, they consist of an outer cortex and inner medulla. The 
adrenal medulla secretes catecholamines (epinephrine and norepinephrine), which are stress 
hormones and are mediators of the sympathetic autonomic nervous system [2]. The adrenal 
cortex itself comprises of three layers viz. zona glomerulosa, zona fasciculata and zona reticu-
laris. These three layers are responsible for secreting mineralocorticoids, glucocorticoids, and 
adrenal androgens (sex hormones) respectively [3]. As the name suggests, mineralocorticoids 
are responsible for maintenance of fluid and mineral (electrolyte) balance; the chief miner-
alocorticoid is aldosterone. Glucocorticoids are involved in regulating glucose metabolism 
(glycolysis and gluconeogenesis) and storage (glycogenesis and glycogenolysis); the proto-
type glucocorticoid is cortisol. The primary adrenal androgen is dehydroepiandrosterone and 
possesses virilizing properties. Cortisol and other related hormones (such as 11-deoxycortisol 
and corticosterone) are collectively referred to as corticosteroids [4].
2. Physiologic effects
Corticosteroids play important physiologic roles in the human body and are referred to as 
“stress hormones” as they prepare the body during periods of physiologic stress. One of the 
most important actions of corticosteroids is their ability to up-regulate glucose synthesis [5]. 
Glycogen is the principal storage form of glucose in humans and is stored in various organs 
of the body, especially the liver. Glycogen is a multibranched polysaccharide and its structure 
consists of a core protein (glycogenin), which gives off multiple branches composed of glucose 
monomers [6]. Glycogen is produced by a biochemical pathway known as glycogenesis, which 
occurs chiefly in the liver. Glycogen is broken down during periods of fasting to provide a sup-
ply of glucose monomers. Glucose monomers can be utilized by all cells of the body through 
the processes of glycolysis. Pyruvate produced during glycolysis can then produce acetyl-
CoA which can enter the Krebs cycle. Oxidation of glucose (in conjunction with the electron 
transport chain) produces adenosine 1,4,5-triphosphate (ATP), which is the energy currency of 
the cell. Stress hormones (such as catecholamines) generally up-regulate gluconeogenesis and 
glycogenolysis to induce hyperglycemia, which helps in fulfilling energy demands of vari-
ous cells of the body [7]. Corticosteroids also induce fasting hyperglycemia by up-regulating 
gluconeogenesis; this is achieved by increasing expression of several key enzymes involved 
in gluconeogenesis including phosphoenol pyruvate-carboxykinase, fructose-1,6-bisphospha-
tase and glucose-6-phosphatase [8]. Cortisol and other corticosteroids are unique in that they 
up-regulate gluconeogenesis while inhibiting glycogenolysis. This seemingly contradictory 
effect of corticosteroids is important in intrauterine life when release of cortisol from the fetal 
adrenal gland helps in building glycogen stores in the fetal liver to prepare for delivery.
Protein metabolism is also affected by corticosteroids. Increased catabolism of proteins to 
amino acids provides a supply of alanine, which can be converted to glucose by the process of 
gluconeogenesis. Cahill cycle (glucose-alanine cycle) refers to a series of chemical reactions in which 
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amino groups and carbon skeletons from muscles are transported to the liver in the form of 
alanine, which are subsequently converted to glucose [9]. An essential enzyme for Cahill cycle 
is alanine aminotransferase (ALT), which is present in both muscles and liver. Alanine amino-
transferase (also known as serum glutamate-pyruvate transaminase [SGPT]) is responsible for 
transferring an amino group from alanine to α-ketoglutarate, which results in the production of 
pyruvate and glutamate [10]. Pyridoxal phosphate is a co-factor for this reaction and is formed 
from pyridoxine (vitamin B
6
). As corticosteroids up-regulate protein catabolism, they induce a 
state of negative nitrogen balance in the body, which is important during periods of starvation.
Corticosteroids have important effects on bone turnover and affect bone mass. Bone is a type 
of connective tissue composed of osteocytes, osteoblasts and osteoclasts [11]. Osteoclasts 
are derivatives of the reticuloendothelial system and are responsible for bone resorption. 
Osteoblasts are mesenchymal origin cells and are responsible for giving rise to osteocytes—
the mature cells that make up bones. Osteoclasts and their progenitors express a receptor on 
their surface for nuclear factor-κB (NFκB) commonly referred to as RANK. Ligand for RANK 
(known as RANKL) is expressed on the surface of osteoblasts and RANK–RANKL interaction 
is necessary for the differentiation and formation of osteoclasts [12]. Osteoprotegerin (OPG) 
is a cytokine receptor that is secreted by stromal cells and osteoblasts, which acts as a decoy 
receptor for RANKL. Secretion of OPG is one of the mechanisms by which the body prevents 
excessive resorption of bones. Due to this reason, OPG is sometimes also referred to as “osteo-
clastogenesis inhibitory factor.” Corticosteroids can affect bone turnover by inhibiting the 
secretion of OPG and increasing RANK–RANKL interaction, which leads to enhanced forma-
tion of osteoclasts. By tipping the balance in favor of osteoclasts, corticosteroids favor bone 
resorption and loss of mineral bone mass [13]. Calcium homeostasis in the body is tightly reg-
ulated by a number of hormones including parathyroid hormone (PTH), calcitonin and other 
hormones. Under physiologic conditions, serum calcium level is not drastically affected by 
corticosteroids. However, in pathologic states including Cushing’s syndrome and Addison’s 
disease, hypocalcemia and hypercalcemia (respectively) may be occasionally seen.
Vascular tone is also affected by corticosteroids, which has important implications during 
states of physiologic stress. Under resting conditions, cortisol and other corticosteroids are not 
necessary for maintaining vascular tone. However, during periods of stress, corticosteroids 
have a “permissive effect” for catecholamines and help in maintaining the vascular tone [14]. In 
patients with severe deficiency of glucocorticoids (such as Addison’s disease), catecholamines 
are ineffective in increasing the blood pressure; this may manifest clinically as overt or ortho-
static hypotension. This is especially important for patients with severe sepsis (or septic shock), 
myxedema coma, pituitary apoplexy and other diseases. Presence of stress hormones (includ-
ing thyroid hormones and corticosteroids) is necessary for the optimal action of catecholamines, 
which helps in the maintenance of vascular tone and blood pressure [15]. This in turn maintains 
adequate perfusion of vital organs and allows the body to cope with physiologic stress.
Fluid status of the body is principally controlled by steroid hormones. Mineralocorticoids (such 
as aldosterone) are primarily responsible for maintaining the fluid and salt balance in the body. 
Renin is a hormone secreted by the juxtaglomerular apparatus of nephrons, which is responsible 
for cleaving angiotensinogen to angiotensin I. Angiotensinogen is produced in the liver and is a 
precursor to angiotensin I, which is produced in the circulation by action of renin. Angiotensin 
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I is then converted to angiotensin II in the pulmonary microvasculature through the action of 
dipeptidyl peptidase (commonly referred to as angiotensin converting enzyme [ACE]) [16]. 
Angiotensin II has at least four important effects in the body: (a) stimulation of aldosterone 
synthesis and secretion; (b) increasing thirst; (c) vasoconstriction; and (d) enhancing activity of 
sodium (Na+)-hydrogen (H+) exchanger in the proximal convoluted tubule of nephrons. The 
overall impact of angiotensin II is to retain salt and water with expansion of the effective circulat-
ing volume [17]. Aldosterone leads to further expansion of the extracellular fluid by increasing 
reabsorption of sodium (Na+) and chloride (Cl−) in the distal convoluted tubule of nephrons. At 
the same time, aldosterone increases tubular secretion of potassium (K+) and loss of hydrogen 
(H+) ions in the urine, which can potentially induce hypokalemia and metabolic alkalosis respec-
tively. The overall effect of the renin–angiotensin–aldosterone system (RAAS) is to retain salt and 
water, thereby expanding the effective circulating volume and blood pressure. Although corti-
costeroids possess mainly glucocorticoid effects, they do have weak mineralocorticoid effects at 
physiologic concentrations. In disease states, and when used therapeutically, corticosteroids can 
have substantial mineralocorticoid activity with clinically significant effects on the body [18].
A number of other effects are also possessed by corticosteroids, which are not evident in physi-
ologic states; however, in disease states, these actions can result in protean manifestations. 
Corticosteroids are necessary for optimal functioning of the body and excess or deficiency of 
these hormones can manifest as Cushing’s syndrome or Addison’s disease respectively. Cushing 
syndrome is most commonly iatrogenic and results from exogenous use of steroids, although it 
can also result from cortisol or adrenocorticotrophic hormone (ACTH)-secreting tumors (such 
as pituitary adenoma, adrenal adenoma or carcinoma, small cell carcinoma of lung, etc.) [19]. 
Common features of this disease include obesity, buffalo lump (lipodystrophy), moon facies, 
purple abdominal striae, easy bruising, depression, psychosis, cataracts, glaucoma, hyperten-
sion, hypokalemia and hypocalcemia. On the other hand, Addison’s disease can be caused by 
auto-immune destruction of the adrenal gland (in developed countries) or infiltration of the adre-
nal gland by infections such as tuberculosis (in developing countries). Hypocortisolism mani-
fests as weakness, fatigue, weight loss, hyperpigmentation of skin (due to increased release of 
ACTH from the pituitary gland), hyponatremia, hyperkalemia, orthostatic or resting hypoten-
sion, hypercalcemia, basophilia and/or eosinophilia [20]. Treatment of these diseases is directed 
at restoring the balance of steroid hormones back to normal. In the case of Cushing syndrome, the 
underlying cause is addressed (e.g. removal of primary tumor); rarely, bilateral adrenalectomy 
with exogenous replacement of steroids may be required. In Addison’s disease, replacement of 
steroid hormones is generally needed for life. These two diseases exemplify the importance of 
corticosteroids and the deleterious consequences of their excess or deficiency on the human body.
3. Mechanism of action
From a therapeutic standpoint, corticosteroids have been exploited most for their anti-inflam-
matory and immunosuppressive effects [21]. While these properties of corticosteroids are not 
evident during physiologic states, they are clinically important in the treatment of numerous 
diseases including auto-immune diseases, neoplastic diseases, inflammatory disorders, rheu-
matologic conditions and infectious diseases (in conjunction with other drugs).
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Inflammation is the response of the body to any noxious stimulus with an aim to eliminate 
the noxious stimulus and start the process of tissue repair. Inflammatory response of the body 
involves leukocytes, chemical mediators and vascular changes. Acute inflammation begins with 
a series of vascular changes that increases blood flow to the inflamed tissue. Chemical media-
tors of inflammation, such as histamine and serotonin, cause arteriolar vasodilation and venous 
vasoconstriction. This in turn promotes the exudation of fluid from the intravascular compart-
ment to the interstitial space [22]. Leukocytes are then recruited to the area of inflammation 
through the expression of selectins on endothelium and integrins on leukocytes. Selectins are 
responsible for weak binding of leukocytes to the endothelium, which results in “rolling” of 
leukocytes along the endothelium. On the other hand, integrins are responsible for high-affinity 
binding of leukocytes (“adhesion”) to the endothelium with pavementing of the endothelium 
with leukocytes. Through the interaction of various cell surface molecules, such as platelet–endo-
thelial cell adhesion molecule-1 (PECAM-1), leukocytes migrate through the microvasculature 
into the interstitium [23]. Neutrophils, monocytes and macrophages can phagocytose microbes 
and other offending agents by binding to their pathogen-associated molecular patterns (PAMPs) 
using pattern recognition receptors (PRRs). Following phagocytosis, microbes are trapped 
inside vacuoles called “phagosomes,” which are then fused with lysosomes to form phagoly-
sosomes. Microbes and dead cells are thus degraded through the action of hydrolytic enzymes 
present inside lysosomes. Neutrophils and macrophages can also generate free radicals through 
the action of enzymes, which can damage different micro-organisms and offending agents [24].
A number of chemical mediators play a crucial role in the process of inflammation. These 
include biogenic amines, prostaglandins, leukotrienes, lipoxins, cytokines, chemokines, com-
plement proteins, bradykinin, nitric oxide and other molecules [25]. Histamine and serotonin 
are biogenic amines and mediate vascular changes implicated in acute inflammation; hista-
mine also causes bronchoconstriction. Prostaglandins are eicosanoids and have a variety of 
actions in the body. PGE
2
 is the mediator of pain, PGF2α causes increased vascular permeabil-ity, PGI
2
 (prostacyclin) causes vasodilation and thromboxane A
2
 causes platelet aggregation 
and vasoconstriction. Leukotrienes are derivatives of arachidonic acid and mediate broncho-
constriction. Lipoxins are lipid-derived autacoids that have a modulatory effect on the overall 
process of inflammation [26]. Bradykinin is a product of the kinin cascade and is derived by the 
action of kallikrein on high-molecular weight kininogen. This molecule irritates bronchiolar 
smooth muscle and mediates cough and vasodilation. Nitric oxide is released from endothe-
lium and causes vasodilation. Complement cascade plays an important role in inflammation 
and is a part of the humoral immune system. Some complement proteins act as opsonins and 
anaphylatoxins. C5a, a complement protein, also causes chemotaxis of leukocytes to the area 
of inflammation. Cytokines are a group of small protein molecules that play various roles in 
the body including chemotaxis of leukocytes (chemokines), communication between leuko-
cytes (interleukins), mounting fever (pyrogens) and so on [27]. All these chemical mediators 
play a crucial role in mounting an inflammatory response and pharmacologic interruption of 
their actions can blunt or modulate the inflammatory response.
Phospholipase A
2
 is an enzyme that is responsible for the synthesis of arachidonic acid from 
phospholipids present in cell membranes of various cells. Arachidonic acid is an important 
lipophilic compound that serves as the precursor for the synthesis of prostaglandins, thrombox-
ane A
2
, leukotrienes and lipoxins (Figure 1). Cyclooxygenase is an enzyme that is responsible 
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for the formation of prostaglandins from arachidonic acid. Non-steroidal anti-inflammatory 
drugs (NSAIDs) and acetaminophen exert their anti-inflammatory effects by inhibiting cyclo-
oxygenase and preventing formation of prostaglandins and thromboxane [28]. Arachidonic 
acid can also be acted upon by 12-lipoxygenase that results in the formation of lipoxins A
4
 and 
B
4
, both of which modulate inflammation by inhibiting neutrophil adhesion and chemotaxis. 
Another enzyme, 5-lipoxygenase, is involved in the synthesis of leukotrienes from arachidonic 
acid. Leukotrienes C
4
, D
4
 and E
4
 induce bronchospasm, vasoconstriction and increased vascu-
lar permeability. Synthesis of arachidonic acid is inhibited by corticosteroids and this effect of 
corticosteroids is exploited therapeutically for treating inflammatory disorders [29].
The anti-inflammatory effects of corticosteroids are chiefly achieved by altering the synthesis of 
chemical mediators of inflammation. When commercially available corticosteroids are adminis-
tered therapeutically, these molecules are readily absorbed and penetrate into various cells of the 
body due to their highly lipophilic nature. Glucocorticoids enter the cytosol of cells and bind to 
the glucocorticoid receptor. The glucocorticoid–receptor complex can repress the expression of 
pro-inflammatory genes by preventing translocation of certain transcription factors (especially 
NFκB) from the cytosol into the nucleus [30]. Moreover, the glucocorticoid–receptor complex can 
translocate into the nucleus and up-regulate transcription of anti-inflammatory genes by binding 
to “zing fingers” of glucocorticoid-response elements (GRE). Glucocorticoids inhibit transloca-
tion of NFκB by inducing the expression of IκBα inhibitory protein, which sequesters NFκB in 
the cytosol and prevents transcription of pro-inflammatory genes [31]. This is in turn inhibits the 
expression of pro-inflammatory genes and results in a blunted inflammatory response.
Figure 1. Arachidonic acid metabolism with cyclooxygenase and lipoxygenase pathways. HPETE = hydroperoxyei-
cosatetraenoic acid.
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One of the most important effects of glucocorticoids is the modulation of gene expression 
of enzymes involved in the metabolism of arachidonic acid. Most notably, glucocorticoids 
reduce the expression of the enzyme phospholipase A
2
, which is responsible for the forma-
tion of arachidonic acid [32]. By inhibiting the formation of arachidonic acid, synthesis of 
prostaglandins, lipoxins, leukotrienes and thromboxane is inhibited. Since arachidonic acid 
metabolites mediate several key steps in the process of inflammation, their inhibition results 
in a blunted inflammatory response. Consequently, margination, chemotaxis and phago-
cytosis by phagocytes are inhibited by corticosteroids, which manifests as an overall anti-
inflammatory effect. Additionally, through inhibition of the NFκB pathway, inflammatory 
cells begin to produce anti-inflammatory cytokines, which down-regulate the overall immune 
and inflammatory response. This has important therapeutic implications for the treatment of 
many diseases in which chronic inflammation lies at the core of their pathogenesis [33].
4. Formulations
Different formulations of corticosteroids are commercially available and have been used in 
a variety of diseases. Tablets, intravenous formulations and intramuscular preparations are 
available for systemic use. Systemic formulations are generally more efficacious as compared 
to other formulations (such as inhaled or topical steroids). However, this greater efficacy 
comes at the cost of increased adverse effects, which may be substantial in some cases [34]. 
Oral formulations are available for various corticosteroids with the most popular ones being 
prednisolone, methylprednisolone, hydrocortisone, and dexamethasone. Given the lipophilic 
nature of steroids, adequate absorption of steroids is achieved in most patients as they read-
ily cross cell membranes of enterocytes [35]. Oral formulations are convenient for patients 
who require chronic use of steroids, such as lung transplant recipients. Tablets are the most 
commonly used oral formulation of corticosteroids. Prednisone syrup and dexamethasone 
oral solution or elixirs are also available, which may be useful for pediatric patients and those 
with feeding tubes. Conversion from one systemic steroid to another requires knowledge of 
equipotent dosages, which are provided in Table 1. Frequency of dosage is determined by 
the half-life and duration of action for individual corticosteroids; for instance, hydrocortisone 
lasts for 8–12 hours whereas dexamethasone may last for 36–72 hours [36].
Parenteral systemic formulations of steroids are also available and have a number of impor-
tant uses. Intramuscular preparations of steroids, such as methylprednisolone or triamcino-
lone acetonide, are often used to provide a delayed release of steroids over a prolonged period 
of time with a relatively steady plasma concentration. Intravenous methylprednisolone and 
hydrocortisone are often used in patients with life-threatening or organ-threatening inflam-
matory conditions. Very high doses of steroids can be given intravenously (termed ‘pulse 
therapy’), which have been postulated to have physicochemical effects on plasmalemma of 
various cells, which may modulate the function of transmembrane proteins [37]. Steroid ther-
apy has also been employed via many other parenteral routes of administration. Intralesional 
triamcinolone acetonide injections have been used for the treatment of several dermatologic 
disorders, such as keloids, alopecia areata, granuloma annulare, lichen planus and psoriasis. 
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Gout and other inflammatory joint disorders have been treated with intra-articular injections 
of steroids. In the field of oncology, intrathecal administration of hydrocortisone along with 
chemotherapeutic drugs has been used for the treatment of leukemia [38].
Inhaled preparations of corticosteroids come in the form of nebulizer solutions, metered-dose 
inhalers or dry powder inhalers. Inhaled formulations are useful for the treatment of various 
airway disorders as these preparations exert their maximal effects locally with minimal sys-
temic absorption. Consequently, the risk of systemic adverse effects is reduced, although oral 
thrush, dysphonia and systemic adverse effects can still occur with long-term use [39]. Most 
notably, children may have deceleration of growth velocity with the long-term use of cortico-
steroids [40]. In adults, long-term use of inhaled corticosteroids (ICS) may lead to accelerated 
loss of bone mass and possible ophthalmic side-effects (such as increased intraocular pressure 
and/or cataracts) [41]. The most commonly used inhaled steroids include beclomethasone, 
fluticasone, budesonide and mometasone. Nebulized delivery of respiratory solutions pro-
vides the best delivery of medications to the lower airways when compared with metered-
dose inhalers or dry powder inhalers. Proper inhaler technique with or without the use of 
spacer devices may provide equivalent effects with powder/inhaled forms of steroids as com-
pared to nebulizer administrations [42].
Topical formulations of steroids are available for use and have been utilized therapeutically 
for a wide variety of dermatologic conditions. Like inhaled forms, topical use of steroids pro-
vides local effects on the skin with some systemic absorption. Consequently, local effects of 
steroids are maximized, while systemic side-effects are minimized. However, use of a large 
amount of topical steroids, especially if continued over a long period of time, can result in sig-
nificant systemic side-effects (as is the case with inhaled steroids) [43]. A number of vehicles 
are available for the topical delivery of steroids including ointments, creams, lotions, gels, 
foams and wet dressings. Topical steroids have been classified on the basis of their potency 
into 7 categories viz. least potent, low potency, lower-mid potency, medium potency, high 
potency, very high potency, and super-high potency. Using the correct vehicle and potency of 
topical steroids is of utmost importance as inadvertent use of a weak steroid preparation may 
lead to treatment failure, while use of a very potent topical preparation can lead to thinning 
and atrophy of the skin [44]. It is important to bear in mind that the potency of topical steroids 
is determined not only by the dermatologic diagnosis, but also by the area and extent of the 
skin that is affected. For instance, genital skin or intertriginous areas are exquisitely sensitive 
Steroids Dexamethasone Methylprednisolone Prednisone Hydrocortisone Fludrocortisone
Glucocorticoid 
effect*
0.75 mg 4 mg 5 mg 20 mg -
Mineralocorticoid 
effect*
- - 50 mg 20 mg 100 mcg
Duration of 
action
36–72 hours 
(long)
12–36 hours 
(intermediate)
12–36 hours 
(intermediate)
8–12 hours 
(short)
12–36 hours 
(intermediate)
*Fludrocortisone has no glucocorticoid effect, while dexamethasone and methylprednisolone have negligible mineral-
ocorticoid effects
Table 1. Comparison of equivalent doses of various steroids.
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to topical steroids, which make them suitable candidates for lower potency topical steroids. 
On the other hand, skin of palms and soles have thick stratum corneum (the uppermost layer 
of epidermis), which necessitates the use of more potent topical steroids.
5. Therapeutic use in respiratory disorders
Steroids have been approved for the use of various respiratory diseases for both pediatric 
and adult populations. Both systemic and inhaled formulations of steroids have been utilized 
for the treatment of various respiratory disorders. In most disorders, steroids exert a thera-
peutic effect through their anti-inflammatory or immunosuppressive effects [21]. In many 
diseases, steroids can be given in the form of short intermittent courses; examples include 
hypersensitivity pneumonitis, eosinophilic pneumonitis, allergic bronchopulmonary asper-
gillosis (ABPA), etc. In some diseases, such as bronchial asthma or chronic obstructive pulmo-
nary disease (COPD), inhaled steroids are continued on a long-term basis as a maintenance 
therapy. Systemic steroid therapy may also be required on a long-term basis in patients with 
systemic disorders or diseases refractory to other therapies, for instance sarcoidosis or col-
lagen vascular diseases. In many diseases requiring long-term immunosuppression, steroid-
sparing agents (such as azathioprine, mycophenolate, cyclosporine, tacrolimus, etc.) can be 
introduced to taper off steroids and mitigate their long-term side-effects [45].
In the following lines, we discuss the use of corticosteroids in the management of various respi-
ratory disorders. A general overview of each of these diseases is provided and along with a holis-
tic view of how steroid therapy works in conjunction with other components of management.
5.1. Asthma
Bronchial asthma is a chronic inflammatory disorder of bronchi and bronchioles that results 
in intermittent and reversible bronchospasm [46]. Clinical features of the disorder include 
recurrent episodes of chest tightness, wheezing and shortness of breath. Most patients have a 
diurnal variation in their symptoms with worsening shortness of breath and cough towards 
the end of the day. Over time, patients tend to develop bronchial smooth muscle hypertro-
phy, goblet cell hyperplasia with hypersecretion of mucus, recruitment of eosinophils and 
a state of chronic inflammation within the airways. Genetic predisposition to type I hyper-
sensitivity has been demonstrated in most patients with asthma, although environmental 
factors also play a central role in triggering attacks of asthma [47]. Asthma has been clas-
sified into multiple subtypes depending on the type of triggers that precipitate attacks of 
asthma viz. atopic asthma, non-atopic asthma, drug-induced asthma, occupational asthma, 
and exercise-induced asthma. Atopic asthma is characterized by a personal or family history 
of atopy, allergic rhinitis, eczema and hypersensitivity to allergens, such as pollens or dust 
mites [48]. In non-atopic asthma, patients do not have hypersensitivity responses to allergens; 
instead, attacks of asthma are precipitated by factors such as viral infections, cold tempera-
ture, inhaled gases (e.g. sulfur dioxide), etc. Drug-induced asthma is precipitated by drugs 
such as NSAIDs or aspirin, which tip the balance towards increased synthesis of leukotrienes 
with consequent bronchospasm. Likewise, occupational asthma is reportedly precipitated 
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by exposure to chemicals (e.g. anhydrides, isocyanates, acids) in various industries, such as 
paints, varnishes, adhesives and resins. Exercise-induced asthma is precipitated by exercise 
and diagnostic testing at rest may be normal in such cases [49]. Irrespective of the type of 
asthma, the core pathogenesis underlying all these types of asthma is similar.
The pathogenesis of asthma entails an inflammatory response affecting the bronchi and bron-
chioles, which is chiefly driven by a type 2 helper T (TH2) lymphocytes. When an environ-mental allergen is inhaled, antigen-presenting cells (APCs) engulf the allergen and present 
it to T lymphocytes. As a consequence of this, a TH2 cell-mediated inflammatory response is mounted. TH2 cells produce an array of cytokines including interleukin (IL)-2, IL-4, IL-5 and IL-13. IL-2 acts upon other T lymphocytes to differentiate them into TH2 cells and promote an amplified response [50]. IL-4 activates B lymphocytes and promotes immunoglobulin class 
switching to immunoglobulin E (IgE) production. IL-5 acts on bone marrow to increase dif-
ferentiation and proliferation of eosinophils. Eotaxin is another cytokine produced by airway 
epithelial cells and serves to recruit eosinophils. IL-13 is believed to stimulate mucus produc-
tion from mucus glands and goblet cells. Through these cytokines, TH2 promote a humoral immune response that results in production of high circulating levels of allergen-specific 
IgE. IgE binds to mast cells and cross-linking of mast cell-bound IgE results in degranu-
lation of mast cells with release of histamine, tryptase and heparin sulfate. Histamine is a 
potent bronchoconstrictor and is the chief mediator of bronchoconstrictor in atopic asthma. 
Repeated exposure to the same allergen results in stronger activation of TH2 lymphocytes. A state of chronic inflammation persists within the bronchioles and results in airway remodeling, 
which is a histopathological hallmark of chronic asthma [51].
Numerous pharmacologic and non-pharmacologic modalities are used in the management 
of patients with asthma. Non-pharmacologic approaches include avoidance of allergens by 
removing carpets from houses, avoiding exposure to animal dander, using personal protective 
equipment while at work (in cases of occupational asthma), maintaining a clean environment 
(reducing exposure to dust mites), and so on. Pharmacologic treatment options include short-
acting β
2
-adrenoceptor agonists (SABA), short-acting muscarinic antagonists (SAMA), long-
acting β
2
-adrenoceptor agonists (LABA), ICS, phosphodiesterase (PDE) inhibitors (such as 
theophylline), anti-leukotrienes (such as montelukast), systemic corticosteroids, and immuno-
therapy (such as omalizumab and mepolizumab) [52]. SABA causes bronchodilation by stimu-
lating β
2
-adrenergic receptors on the smooth muscle layer of bronchioles. As β
2
-adrenoceptors 
are G-protein coupled receptors (GPCRs), their stimulation (G
s
) results in activation of adeny-
lyl cyclase and increased levels of cyclic adenosine monophosphate (cAMP) inside smooth 
muscle cells. This in turn activates protein kinase A and results in phosphorylation of myosin 
light chain kinase, which essentially deactivates this enzyme. Consequently, dephosphoryla-
tion of myosin light chain occurs via the unregulated action of myosin light chain phosphatase, 
which causes smooth muscle relaxation and bronchodilation. PDE inhibitors (such as theoph-
ylline and aminophylline) act in a similar manner by inhibiting degradation of cAMP (caused 
by PDE), which results in increased level of cAMP in smooth muscle cells [53]. This results in 
bronchodilation in the same manner as SABA, except that the β
2
-adrenoceptor and adenylyl 
cyclase are not involved in this pathway. SAMA causes bronchodilation by blocking musca-
rinic receptors and preventing vagal stimulation. Moreover, SAMA also blocks  muscarinic 
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M
3
 receptors present on smooth muscle cells of bronchioles and prevent bronchoconstriction 
in response to a variety of stimuli. Anti-leukotrienes effectively block bronchoconstriction in 
response to leukotrienes C
4
, D
4
 and E
4
 by either blocking their target receptors (montelukast) 
or reducing their synthesis (zileuton). Omalizumab is a humanized monoclonal antibody 
directed against free circulating IgE and reduces levels of IgE, thereby reducing sensitivity to 
allergens [54]. Mepolizumab is an antibody that binds IL-5 and blocks the signaling pathways 
activated by IL-5 [55]. While mepolizumab reduces activation and recruitment of eosinophils, 
its exact mechanism of action in the treatment of asthma remains unclear.
Corticosteroids act through multiple pathways in controlling asthma and are useful in the 
treatment of acute exacerbations of asthma as well as long-term maintenance therapy [56]. 
Systemic and ICS act in a similar manner and their chief effect is reduction of airway inflam-
mation by blocking the NFκB pathway. Corticosteroids reduce the expression of the enzyme 
phospholipase A
2
, which results in decreased synthesis of arachidonic acid and its metabo-
lites [21]. Reduced levels of leukotrienes promote bronchodilation and relieve airway obstruc-
tion. Anti-inflammatory activity of corticosteroid over a long period of time can retard airway 
remodeling, thereby reducing smooth muscle cell hypertrophy, thickening of the basement 
membrane, and goblet cell hyperplasia [56]. Corticosteroids also have immunosuppressive 
properties, which enable them to reduce levels of IgE and inhibit proliferation of TH2 and B lymphocytes [31]. By reducing transcription of IL-4 and IL-5, corticosteroids also inhibit 
eosinophil recruitment and activation. Furthermore, by blocking the synthesis of IL-13, mucus 
secretion is reduced, which can further relieve airway obstruction.
Corticosteroids form a cornerstone of the management of asthma. Management of acute 
exacerbation of asthma requires accurate assessment of the severity of the exacerbation and 
appropriate triage [57]. Airway, breathing and circulation need to be secured as in any other 
emergency condition. Inhaled oxygen and SABA therapy are the first and foremost in the 
management of acute exacerbations. Intravenous terbutaline (β
2
-agonist) may also be used. 
Systemic corticosteroids should also be administered to all patients with a moderate to severe 
acute exacerbation of asthma, although their onset of action is after several hours. If patients 
do not respond to acute SABA therapy, intravenous magnesium sulfate and/or aminophylline 
infusion may also be considered. Patients with signs of fatigue (such as mental status changes 
or normalization of arterial carbon dioxide levels) may require endotracheal intubation and 
mechanical ventilation. In patients with long-standing asthma, a stepwise approach to ther-
apy has been proposed [58]. Again, accurate assessment of asthma control is essential to tailor 
therapy to individual patients. The first step of therapy consists of non-pharmacologic mea-
sures and rescue medication (inhaled SABA) as needed. The second step is to add a low-dose 
ICS (controlled medication) along with a rescue medication (inhaled SABA) as needed. The 
third step is to either add LABA along with ICS or to increase the dose of ICS to medium dose. 
The fourth step is to use LABA along with medium-dose ICS therapy, or to add another agent 
(such as an anti-leukotriene or a PDE inhibitor). The fifth step is to use high-dose ICS therapy 
along with LABA with or without other agents mentioned in step 4. The sixth step is the use 
of systemic corticosteroids and/or immunotherapy along with other therapies as mentioned 
in steps 1–4. Generally, refer to an asthma specialist should be considered for patients who 
persistently require step 4 or higher therapies [59].
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5.2. Chronic obstructive pulmonary disease
COPD refers to a group of obstructive lung diseases which are characterized by progressive 
and irreversible limitation to airflow in the setting of a chronic inflammatory state of the air-
ways and/or lung parenchyma. Generally, emphysema and chronic bronchitis are two entities 
included under the heading of COPD, although these entities are not mutually exclusive and 
may co-exist in a patient. Emphysema is characterized by destruction of the wall and inter-
stitium of the lung parenchyma leading to irreversible dilatation and enlargement of acini, 
thereby leading to air trapping within the lungs [60]. Depending on the etiology of emphy-
sema, it can affect either whole of the respiratory acinus (pan-acinar emphysema) or portions 
of it (centriacinar, distal acinar or irregular emphysema). Clinically, patients with emphysema 
have been referred to as ‘pink puffers’ as they tend to have a lean built, breath with pursed 
lips, are often tachypneic, and appear pink due to hypercapnia (carbon dioxide retention). 
In contrast, chronic bronchitis is characterized by the presence of a productive cough for ≥3 
consecutive months over a period of at least 2 years [61]. Interestingly, chronic bronchitis has 
a ‘clinical’ definition as opposed to emphysema, which is defined on the basis of morphologic 
and histopathological features. Patients with chronic bronchitis often have pathology affect-
ing the larger airways (i.e. bronchi) as opposed to the air-space (parenchymal) disease seen 
in patients with emphysema. ‘Blue bloaters’ is a term used to refer to patients with chronic 
bronchitis as they often have resting cyanosis due to hypoxemia and polycythemia, and fluid 
retention due to right-sided heart failure (‘cor pulmonale’). All patients with COPD do have 
a number of features in common. All patients have a demonstrable obstructive defect on pul-
monary function testing, which differentiates them from those with restrictive lung diseases. 
Moreover, patients with COPD generally have a progressive, irreversible obstructive pro-
cess, which differentiates them from the intermittent, reversible obstruction seen in patients 
with asthma [62]. From a physiologic standpoint, all patients with COPD have a higher than 
normal lung compliance, which increases the tendency for alveoli to collapse, and makes 
expiration difficult. Air trapping results in elevated residual volume and increased total lung 
capacity, but a reduced forced vital capacity. Consequently, patients have an elevated func-
tional residual capacity at rest. Moreover, as the disease process progresses, patients with 
emphysema develop a defect in diffusion of gases and impaired gas exchange. All these pro-
cesses increase the work of breathing and impair oxygenation and ventilation [63].
Cigarette smoking has been implicated as the main etiologic factor in the pathogenesis of 
COPD [64]. Exposure to inhaled pollutants and toxins leads to production of free radicals 
and oxidant stress that can damage the airway epithelial lining. On-going exposure to such 
inhaled pollutants leads to accumulation of inflammatory cells (such as neutrophils, macro-
phages and lymphocytes) with release of proteolytic enzymes and a cascade of pro-inflam-
matory cytokines. This process of active chronic inflammation leads to destruction of elastin 
contained in the pulmonary interstitium, which leads to dilatation of acini — the hallmark 
feature of emphysema. Cigarette smoke in particular has been shown to inhibit α
1
-antitrypsin 
— an enzyme that inhibits neutrophilic elastase and prevents destruction of elastin. Inhibition 
of α
1
-antitrypsin by cigarette smoking leads to unregulated activity of neutrophilic elastase 
and consequent destruction of acini. Similarly, in patients with congenital deficiency of α
1
-
antitrypsin, pan-acinar emphysema sets in early in life, in the absence of any history of ciga-
rette smoking [65]. In patients with chronic bronchitis, cigarette smoking leads to hyperplasia 
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of mucus-secreting glands in the larger airways; this is an adaptive response of the body to the 
irritants contained in cigarette smoke. Accumulation of mucus plugs, co-existent emphysema 
and bronchiolitis results in airflow obstruction in patients with clinical features of chronic 
bronchitis [63]. In cases of both emphysema and chronic bronchitis, the core feature of patho-
genesis is on-going exposure to inhaled toxins and a state of chronic inflammation within the 
smaller airways [60]. This explains why smoking cessation is the most important therapeutic 
intervention in patients with COPD and reduces overall mortality in such patients.
Corticosteroids have an important role in the overall management of patients with COPD. As 
is the case with asthma, corticosteroids provide a therapeutic effect in patients with COPD 
by inhibiting bronchoconstriction, promoting bronchodilation, suppressing the immune 
response, and having an overall anti-inflammatory effect [66]. In patients with acute exacerba-
tion of COPD, SABA and SAMA are the first-line therapeutic agents. The use of non-invasive 
positive pressure ventilation (NIPPV) can reduce the need for endotracheal intubation and 
reduces overall mortality in such patients. Systemic corticosteroids and antibiotics also have 
an important role in the treatment of acute exacerbation of COPD, although the onset of their 
action is delayed. Nebulized corticosteroids (such as budesonide) may also be added along 
with other therapies. In patients with refractory respiratory failure or contraindications to 
NIPPV, endotracheal intubation and mechanical ventilation may become necessary. In the 
management of patients with stable COPD, ICS are a cornerstone of therapy. The optimal ther-
apy for such patients is based on their degree of airflow limitation (quantified by the forced 
expiratory volume in first second of expiration [FEV
1
]) and clinical symptoms (quantified by 
the COPD assessment test [CAT] and/or modified Medical Research Council [mMRC] scores) 
[67]. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) classifies patients 
into one of four stages (I–IV) depending on their degree of airflow limitation (FEV
1
 ≥ 80%, 
FEV
1
 50–79%, FEV
1
 30–49% and FEV
1
 < 30% respectively). In patients with GOLD stage III–
IV COPD, ICS should be used in conjunction with other therapies [68]. As in patients with 
asthma, SABA or SAMA are used as rescue medications as needed. LAMA alone or LABA 
combined with ICS may be combined with ICS depending on the degree of airflow limitation 
and clinical symptoms in individual patients. Roflumilast, a PDE inhibitor, may also be used 
in patients with COPD who have frequent exacerbations despite other treatment modalities 
[69]. In patients with advanced COPD, lung volume reduction surgery or lung transplant 
may be needed to improve quality of life [70]. In patients with advanced COPD who have a 
limited life expectancy and/or contraindications to lung transplant, hospice care may be the 
best strategy to improve patients’ symptoms.
5.3. Pneumonia
Pneumonia is a term often used to indicate an infection affecting the pulmonary parenchyma. 
Pneumonitis is a term that specifically refers to any inflammatory process affecting the pul-
monary parenchyma, whether infective in origin or otherwise. However, in different publica-
tions, the two terms are often used interchangeably. For the purpose of this chapter, we use 
the term ‘pneumonia’ to refer specifically to infections affecting the pulmonary parenchyma.
Pneumonia is an extremely common illness affecting approximately 450 million people a 
year and is also a leading cause of death among all parts of the world and across all age 
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groups [71]. In the United States, pneumonia alone accounts for almost one-sixth of all deaths. 
These figures seem plausible as the epithelial lining of the lungs are continuously exposed 
to the atmosphere which contains a high burden of pollutants and microbes. Impairment 
in host immunity, mucociliary apparatus and/or cough reflex can predispose people to the 
development of pneumonia. Acute bacterial pneumonias tend to have an acute onset of a 
lobar pneumonia with exudation of fibropurulent material in the alveoli and hepatization 
(consolidation) of lungs. Intracellular microbes cause an atypical pneumonia with a subacute 
presentation and mononuclear interstitial infiltrates. Chronic pneumonia is usually second-
ary to fastidious mycobacteria or fungal infections, which lead to granulomatous inflamma-
tion and possible cavitation of lung parenchyma. A variety of microbial pathogens can cause 
pneumonia and the predisposition to infection with a particular organism is determined 
by several factors, such as age, co-morbidities, vaccination status, use of immunosuppres-
sive drugs, exposure to animals, presence of microbial reservoirs, hospitalization status, 
presence of endotracheal or tracheostomy tube, alcoholism, smoking, malnutrition, and so 
on and so forth [72]. Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, 
Legionella pneumophila, Chlamydia pneumoniae, Mycoplasma pneumoniae, Staphylococcus aureus, 
Pseudomonas aeruginosa, Klebsiella pneumoniae, Mycobacterium tuberculosis and Pneumocystis 
jiroveci are some of the well-known causative organisms of pneumonia. While the aforemen-
tioned list is by no means exhaustive, a causative organism cannot be isolated in most cases of 
community acquired pneumonia (CAP) [73]. A number of explanations have been proposed 
to explain this phenomenon with the most likely explanation being that a significant propor-
tion of patients have pneumonia secondary to viruses, which cannot be isolated by routine 
microbiological methods.
Corticosteroids are not routinely used in all cases of pneumonia. From a theoretical per-
spective, the use of corticosteroids in patients with pneumonia would seem counterintui-
tive. Pneumonia is an infection of the pulmonary parenchyma and use of antimicrobials 
seems to be the prime management. Corticosteroids have been avoided in most cases of 
pneumonia due to concerns that their immunosuppressive effects may actually worsen the 
underlying infection. However, corticosteroids do have a role to play in selected patients 
with pneumonia. The most well-established use of corticosteroids is in patients with severe 
Pneumocystis jiroveci pneumonia as defined by a resting arterial partial pressure of oxygen 
(PaO
2
) of less than 70 mm Hg or an alveolar–arterial (A–a) gradient of PaO
2
 of 35 mm Hg or 
more (both on room air) [74]. In such patients, corticosteroids have been shown to provide 
a clear benefit in terms of overall mortality and reduction in respiratory failure. Apart from 
this, there have been several studies that have assessed the use of steroids in patients with 
severe pneumonia in general. A randomized placebo-controlled trial by Torres et al. dem-
onstrated that the use of a short course of methylprednisolone among patients with severe 
CAP reduced treatment failure [75]. A meta-analysis of 12 randomized clinical trials pub-
lished in 2015 concluded that the use of systemic corticosteroids in adults hospitalized with 
CAP may reduce overall mortality by 3%, decrease hospital stay by 1 day and cut need for 
mechanical ventilation by 5% [76]. Clinical guidelines generally recommend that steroids be 
considered for all patients with CAP requiring hospitalization, especially those requiring 
admission to the intensive care unit, although the benefits and harms should be weighed on 
a case-by-case basis.
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5.4. Allergic bronchopulmonary aspergillosis
ABPA is a pulmonary disorder characterized by a hypersensitivity reaction to the allergens of 
the fungus Aspergillus fumigatus, which occurs in patients with a history of bronchial asthma 
or cystic fibrosis (CF). [77] ABPA has been reported to occur in 1–3% of patients with asthma, 
while in patients with CF, its prevalence may be as high as 10% [78]. A. fumigatus is a spore-
forming mold that occurs ubiquitously in nature. This fungus is medically important because 
it has been implicated in a number of diseases viz. ABPA, aspergilloma, invasive pulmonary 
aspergillosis, allergic fungal rhinosinusitis and bronchial asthma. In patients with long-stand-
ing asthma or CF, A. fumigatus spores can grow within the lumen of airways and lead to the 
formation of hyphae (molds). These fungal hyphae can trigger an IgE-mediated hypersensitiv-
ity which results in bronchial inflammation and airway destruction. Clinically, ABPA manifests 
as a worsening of asthma or CF with patients complaining of wheezing and cough. Laboratory 
investigations may reveal eosinophilia and elevated levels of total IgE. Skin prick tests to 
Aspergillus and precipitins to A. fumigatus are positive. Radiologic studies may reveal fleeting 
pulmonary opacities in the acute stage and signs of central bronchiectasis in longstanding cases. 
Mucus plugging within the larger airways may be visible on roentgenograms and computed 
tomograms may lead to a characteristic “finger-in-glove” appearance [77]. A diagnosis of ABPA 
should be suspected in patients with a history of previously controlled asthma or CF, who 
develop unexplained worsening of their disease. Diagnostic criteria have been published in 
the literature in order to enable clinicians to vouchsafe a diagnosis of ABPA with certainty [79].
Management of ABPA entails the achievement of two separate goals: (a) attenuating the 
hypersensitivity response to A. fumigatus; and (b) decreasing the overall burden of A. fumiga-
tus allergens. Systemic corticosteroid therapy is useful to achieve the former goal, while anti-
fungal therapy (typically itraconazole) is required for the latter [77]. Prednisone in a dose 
of 0.5–2.0 mg/kg/day (or an equivalent) is often employed as first-line therapy. This dosage 
is maintained for a period of 1–2 weeks, beyond which the dosage can be modified to an 
alternate day regimen. Depending on the patient’s response, dose of steroids can be reduced 
slowly and gradually weaned off over a period of 2–3 months. In patients who relapse when 
the dose of corticosteroids is reduced, itraconazole therapy can be especially useful [80]. As 
discussed previously for asthma and COPD, steroids afford a therapeutic effect in ABPA 
owing to their anti-inflammatory, immunosuppressive and bronchodilator effects. Recent 
studies have explored the role of omalizumab in the management of ABPA [81]. Small-scale 
studies suggest that omalizumab may be useful as a steroid-sparing agent in patients with 
either asthma or CF who develop chronic ABPA [82].
5.5. Sarcoidosis
Sarcoidosis is a multisystem disorder of unknown etiology characterized by the formation 
of non-caseating epithelioid cell granuloma. This disorder occurs 10 times more frequently 
among African Americans as compared to Caucasians and the incidence is higher among 
young and middle-aged women. Interestingly, this disease affects non-smokers more often 
than people who smoke. Most commonly, the disease may be discovered incidentally when 
a chest radiograph reveals bilateral hilar lymphadenopathy. Patients may also present with 
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a variety of clinical features including uveitis, xerophthalmia, parotidomegaly, xerostomia, 
lupus pernio, skin nodules, erythema nodosum, hypercalcemia, cardiac conduction system 
abnormalities, hepatomegaly and pulmonary infiltration. Given the undetermined etiology 
of sarcoidosis, it is a histopathological diagnosis of exclusion [83]. Nevertheless, two clinical 
variants of sarcoidosis are well-recognized and may suggest a diagnosis of sarcoidosis in the 
absence of histopathological evidence. Heerfordt-Waldenström syndrome refers to a constel-
lation of clinical findings viz. fever, uveitis, parotidomegaly and facial palsy. Uveoparotid 
fever is another term used to refer to this syndrome and, in the appropriate setting, may obvi-
ate the need for a biopsy [84]. Another variant of sarcoidosis, Löffgren’s syndrome, has been 
classically described in the literature, although it may be somewhat less specific as compared 
to uveoparotid fever. Löffgren’s syndrome refers to a triad of erythema nodosum, arthralgia 
(or arthritis) and bilateral hilar lymphadenopathy [85]. Generally, women who present with 
Löffgren’s syndrome tend to have a better prognosis compared to others. The diagnosis of 
sarcoidosis requires histopathological evaluation and is one of exclusion since its etiology is 
unknown. The hallmark feature on biopsies is the presence of non-caseating granuloma in 
different organs and tissues of the body without an alternative explanation. Laboratory inves-
tigations may also reveal elevated levels of ACE, although this is a non-specific finding. The 
differential diagnosis includes all granulomatous diseases, such as tuberculosis, histoplasmo-
sis, berylliosis, silicosis and cat-scratch disease [83].
Management of sarcoidosis is dependent upon the severity and extent of the disease at the time 
of diagnosis. Pulmonary sarcoidosis has been traditionally described to have four stages [86]. 
Stage I refers to the presence of hilar lymphadenopathy and/or mediastinal lymphadenopathy 
in the absence of any lung infiltration. Stage II refers to the presence of pulmonary reticular 
opacities (predominantly in upper lung zones) along with hilar and/or mediastinal lymphade-
nopathy. Stage III refers to the presence of pulmonary fibrosis and/or reticular infiltrates with 
resolution of hilar and/or mediastinal lymphadenopathy. Stage IV refers to an advanced stage 
of “burnt out” disease in which diffuse pulmonary fibrosis with volume loss and bronchiectasis 
is evident in the absence of any lymphadenopathy. Fortunately, a substantial proportion of 
patients with pulmonary sarcoidosis do not require treatment as most of them have asymptom-
atic, non-progressive disease. Treatment is necessary for patients who have severe disease at the 
time of presentation, those who report bothersome symptoms, or those who demonstrate evi-
dence of progressive disease upon follow-up [87]. Likewise, in patients with extra-pulmonary 
disease, treatment is generally indicated to prevent end-organ damage. First-line treatment is 
to begin prednisone at a dose of approximately 40 mg/day (0.6 mg/kg) and continue for about 
4–6 weeks. If there is no clinical and/or radiographic improvement, this dose of prednisone (or 
an equivalent steroid) can be continued for another 4 weeks. Once the patient shows evidence of 
clinical improvement, reduction in dosage of steroids can be started. There is no evidence avail-
able to support a particular steroid tapering schedule. Most clinicians would gradually reduce 
the dose of prednisone to 10–15 mg/day (approximately 0.2 mg/kg); this maintenance dose of 
prednisone (or an equivalent steroid) would then be continued for a period of approximately 
6 months with frequent monitoring of pulmonary function tests (PFTs) and radiologic studies. 
The usual duration of treatment with prednisone (or equivalent steroid) is almost 1 year. In 
cases where patients have disease refractory to steroids, patients experience relapses when ste-
roids are tapered, or patients develop serious adverse effects related to steroids, steroid-sparing 
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immunosuppressive agents (methotrexate,  azathioprine or biologic agents) can be tried [88]. 
For patients who are at risk of steroid-induced adverse effects and have stage I-II pulmonary 
disease (or evidence of slowly progressive disease), inhaled corticosteroid therapy may be a fea-
sible alternative to systemic corticosteroids [89]. Budesonide 800–1600 mcg inhaled twice daily 
has been most studied in this context. Fluticasone propionate 500–1000 mcg inhaled twice daily 
is also a possible alternative option.
5.6. Collagen vascular diseases
Collagen vascular diseases comprise of a group of disorders characterized by auto-immunity 
to antigens contained within blood vessels and extracellular matrix of various organs. A large 
number of diseases affecting connective tissue of the body are included under this heading. A 
substantial proportion of rheumatologic diseases and auto-immune vasculitides are included 
in this category with the most notable ones being systemic sclerosis (SSc), polymyositis (PM), 
dermatomyositis (DM), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), gran-
ulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA), 
microscopic polyangiitis (MPA), Goodpasture syndrome (GPS) and relapsing polychondritis 
(RPC). Sometimes, vascular diseases are also included in this category irrespective of whether 
auto-immunity is implicated in pathogenesis or not.
Nearly all collagen vascular diseases can affect the lung in a variety of ways. This is not 
surprising since the lungs are rich in both connective tissue and blood vessels. Abundant 
pulmonary vasculature is necessary for gaseous exchange, while abundant collagen and 
elastin fibers in the interstitium are necessary to support the dynamic chest wall–lung 
breathing system [90]. In the following lines, we briefly discuss the spectrum of pulmo-
nary pathologies seen in various collagen vascular diseases and the role of steroids in their 
management.
SSc is a disorder characterized by progressive fibrosis affecting multiple organs of the body 
including the skin, kidneys, lungs and other organs [91]. Within the pulmonary system, SSc 
can lead to the development of ground-glass opacities, which can slowly progress to fibro-
sis of the lung parenchyma. The most common pattern of pulmonary fibrosis seen in SSc is 
similar to that of usual interstitial pneumonitis (UIP) and may be histologically indistinguish-
able from rheumatoid lung or idiopathic pulmonary fibrosis (IPF). In some cases, SSc may 
involve the lung in a pattern similar to that of idiopathic non-specific interstitial pneumonitis 
(NSIP). Progressive pulmonary impairment in SSc is a sign of worse prognosis and mandates 
aggressive treatment [92]. The decision to start treatment with immunosuppressive agents 
is based on clear evidence of progressive pulmonary damage as demonstrated by radiologic 
worsening or decline in pulmonary function as measured by PFTs. Two pharmacologic agents 
have been studied for the treatment of SSc-related interstitial lung disease (ILD): mycopheno-
late and cyclophosphamide [93]. Mycophenolate is often prescribed as monotherapy and the 
usual duration of immunosuppressive therapy is approximately 2 years. Cyclophosphamide 
therapy can be given as intravenous injections or oral therapy and it is generally combined 
with corticosteroid therapy. Oral cyclophosphamide is given daily and necessitates a higher 
cumulative dosage of the drug; on the other hand, intravenous cyclophosphamide is given 
once monthly and allows a lower cumulative dosage with a lower incidence of adverse effects. 
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Cyclophosphamide therapy is continued for a few months and thereafter, it is transitioned 
to an alternative immunosuppressive agent (such as azathioprine or mycophenolate). Most 
clinicians prefer a daily oral dosage of low-dose prednisone (7.5–10 mg) along with cyclo-
phosphamide as it is associated with a lower incidence of scleroderma renal crisis. However, 
some small studies have also reported the use of pulse-dose methylprednisolone along with 
cyclophosphamide [94]. Generally, pulse steroid therapy should be reserved for patients with 
SSc who have another organ-threatening manifestation necessitating their use.
PM and DM are auto-immune diseases that primarily affect muscles and skin, but in severe 
cases, involvement of other organ systems (including the respiratory system) can occur. The 
pathogenesis of PM entails a primary injury to skeletal muscles that is mediated by T lympho-
cytes, while in DM, immune complex deposition occurs in blood vessels and skin followed 
by complement activation that leads to injury and inflammation of the skin and muscles [95]. 
Pulmonary manifestations may be due to aspiration pneumonitis (a consequence of bulbar 
muscle weakness), respiratory failure (secondary to diaphragmatic involvement or chest wall 
muscle weakness) and/or acute alveolitis. ILD associated with PM or DM has been associated 
with the presence of antibodies against aminoacyl-transfer ribonucleic acid (tRNA)–synthe-
tase and can occur as part of the antisynthetase syndrome [96]. The spectrum of ILD asso-
ciated with PM/DM ranges from a chronic, slowly progressive UIP to an acute interstitial 
pneumonitis with diffuse alveolar damage (DAD); NSIP or bronchiolitis obliterans organizing 
pneumonitis (BOOP) can also occur [97]. Depending on the severity of the disease, glucocor-
ticoid therapy alone or in association with other immunosuppressive agents may be required. 
Since most patients with PM/DM require systemic glucocorticoid therapy, such corticoste-
roid therapy may suffice for the pulmonary manifestations as well in many cases. In patients 
with severe disease at baseline or rapidly progressive ILD, pulse-dose methylprednisolone 
therapy followed by systemic glucocorticoid therapy (such as prednisone 1 mg/kg/day) along 
with cyclophosphamide (or other immunosuppressive agents) may be required. Intravenous 
immunoglobulin (IVIG) and/or rituximab have also been used in severe cases [98]. In most 
patients who receive glucocorticoid therapy, another immunosuppressive agent (usually aza-
thioprine or mycophenolate) is also started at the same time and continued for a prolonged 
period of time (as glucocorticoids are tapered off).
SLE is a systemic auto-immune disease with protean manifestations that can affect nearly 
every organ-system of the body, but, occurs more frequently in women. Diagnosis is based 
on exclusion of alternative diagnoses and by applying the classification criteria proposed by 
the American College of Rheumatology (1997) or Systemic Lupus International Collaborating 
Clinics (2012) [99]. Pulmonary manifestations of SLE include pleuritis or pleural effusions, 
pulmonary hypertension, diffuse alveolar hemorrhage (DAH), acute interstitial pneumoni-
tis, ILD and/or shrinking lung syndrome (SLS) [100]. ILD associated with SLE can take one 
of several histologic forms including NSIP, UIP, BOOP, lymphocytic interstitial pneumoni-
tis (LIP), follicular bronchitis and/or nodular lymphoid hyperplasia. The general approach 
to the management of these pulmonary manifestations is similar to that for PM/DM asso-
ciated ILD. Aggressive immunosuppressive therapy (i.e. pulse steroid therapy along with 
cyclophosphamide, rituximab or IVIG) is used for patients with acute interstitial pneumo-
nitis or DAH. Plasmapheresis may also be employed for the management of patients with 
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DAH. NSAID therapy (if not contraindicated) is used for patients with pleuritis [101]. Long-
term immunosuppressive therapy may be required for patients with ILD or SLS.
RA is an auto-immune disorder that results in chronic, symmetric, progressive, erosive poly-
arthritis which can affect any synovial joint of the body. Extra-articular manifestations of this 
disease are common and occur in 20–40% of affected patients. Pulmonary manifestations may 
include arthritis of the cricoarytenoid joints, vasculitis affecting the recurrent laryngeal nerve, 
bronchiolitis obliterans, pleuritis with pleural effusions, pulmonary nodules, pulmonary hyper-
tension and/or UIP [102]. Management of RA is with disease modifying anti-rheumatoid drugs 
and/or biologic agents [103]. NSAIDs may be used for management of pain. Short courses of 
systemic corticosteroids are used to manage acute exacerbations of RA. Systemic corticosteroid 
therapy is also useful for patients who develop rheumatoid vasculitis or bronchiolitis obliter-
ans. ILD associated with RA is treated in a similar fashion as that due to SLE or PM/DM [104].
GPA, EGPA and MPA are small-vessel vasculitides associated with the presence of antineutro-
phil cytoplasmic antibodies (ANCA). GPA is a necrotizing, granulomatous vasculitis that fre-
quently affects the nose, paranasal sinuses, upper airways, lungs and kidneys [105]. EGPA is 
a granulomatous vasculitis that is often associated with a history of asthma and eosinophilia, 
but can involve multiple organ-systems of the body [106]. MPA is another ANCA-related 
small-vessel vasculitis that is non-granulomatous and can affect multiple organ-systems of 
the body, although it usually spares the paranasal sinuses and upper airways [107]. GPS is 
an auto-immune disorder characterized by the formation of auto-antibodies against type IV 
collagen present in basement membrane. This disease principally affects the alveolar and glo-
merular basement membranes resulting in DAH and rapidly progressive glomerulonephritis 
respectively [108]. DAH and/or DAD can also occur in GPA, EGPA or MPA. Treatment of 
these disorders entails aggressive immunosuppression; pulse steroid therapy is combined 
with either rituximab or cyclophosphamide therapy. IVIG and/or plasmapheresis are also 
used in conjunction with immunosuppression. Patients who receive cyclophosphamide ther-
apy are usually switched over to an alternative immunosuppressive agent, such as azathio-
prine or methotrexate. Patients who received rituximab initially may be maintained on the 
same agent or switched over to azathioprine or methotrexate [109].
RPC is a rare auto-immune disease that leads to inflammation and destruction of cartilaginous 
structures of the body. Auricular chondritis (sparing the earlobe), nasal chondritis (may lead 
to saddle-nose deformity), scleritis (or episcleritis), orbital pseudotumor, non-erosive arthri-
tis, laryngeal inflammation, tracheal stricture, bronchial obstruction with post-obstructive 
pneumonia, and/or mitral or aortic regurgitation are some of the prominent clinical features 
of this disease [110]. Approximately one-third of cases occur in association with other rheu-
matologic diseases or malignancy. Patients with auricular or nasal chondritis and/or arthritis 
in the absence of other organ involvement can be treated with NSAIDs alone. Systemic cor-
ticosteroid therapy is used in patients with life or organ-threatening disease [111]. Dapsone 
or other immunosuppressive agents may be used in combination with, or in place of, corti-
costeroids; evidence does not support the use of any particular immunosuppressive agent 
over others. Surgical treatment or airway stenting may be required in patients who develop 
laryngeal or tracheal disease [112].
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5.7. Eosinophilic pneumonitis
Eosinophilic pneumonitis may present either as an acute eosinophilic pneumonia or a more 
indolent chronic eosinophilic pneumonia. Patients with acute idiopathic eosinophilic pneu-
monia generally present with an acute febrile illness and progressive respiratory failure [113]. 
Most patients have a history of new onset or resumption of cigarette smoking, although 
heavy inhalational exposure to fine sand and dust may also precipitate this illness. Peripheral 
eosinophilia is generally absent at presentation, although it may develop later in the disease. 
Computed tomography usually shows bilateral patchy ground-glass opacities or reticular 
infiltrates. Bronchoalveolar lavage (BAL) may reveal a preponderance of eosinophils. Lung 
biopsies usually show marked eosinophilic infiltration of the interstitium and alveolar spaces 
with DAD and absence of hemorrhage or granuloma [114]. Treatment is with systemic corti-
costeroid therapy (usually prednisone 1 mg/kg) continued for a period of 2 weeks followed by 
a gradual taper over the next 4 weeks. Most patients respond dramatically to steroids within 
24–72 hours and respiratory failure resolves rapidly [115].
Chronic eosinophilic pneumonia is an idiopathic disorder that presents with cough, fever, 
dyspnea and wheezing that progress over a period of several weeks to months. Radiologic 
findings of this disorder have been classically described as the “photographic negative of 
pulmonary edema” i.e. bilateral peripheral pleural-based opacities [116]. BAL reveals a pre-
dominance of eosinophils with the eosinophil count often exceeding 25% of leukocyte count. 
BAL and/or lung biopsy are also useful in excluding alternative causes, such as drug-induced 
or infectious causes. Treatment of chronic eosinophilic pneumonia is similar to that for acute 
eosinophilic pneumonia, although systemic corticosteroid therapy is generally tapered slowly 
over a period of 6 months (or more) [117].
5.8. Lymphocytic interstitial pneumonitis
LIP is characterized by benign polyclonal proliferation of lymphocytes with infiltration of 
pulmonary interstitium and alveolar spaces with lymphocytes and plasma cells. This dis-
order often occurs in association with rheumatologic diseases or human immunodeficiency 
virus (HIV) infection [118]. Patients may be asymptomatic or they may present with cough, 
dyspnea and/or constitutional symptoms. Radiologic studies may reveal ground-glass opaci-
ties, centrilobular nodules (or masses), septal thickening and/or lung cysts. Thoracoscopic or 
open lung biopsies are necessary in most cases to confirm the diagnosis and exclude alterna-
tive diseases [119]. Treatment of patients with asymptomatic disease may be watchful wait-
ing with frequent monitoring. For patients with symptomatic disease, systemic corticosteroid 
therapy (usually prednisone 0.5 mg/kg/day) is used and gradually tapered over a period 
of 6–12 months. For patients who do not respond to steroids or relapse during taper, other 
immunosuppressive agents (azathioprine, cyclosporine, cyclophosphamide or rituximab) 
may be used [120]. For patients with HIV infection, highly active antiretroviral therapy is 
used as first-line treatment (instead of corticosteroid therapy). However, corticosteroid ther-
apy will be needed for patients with HIV infection who continue to experience worsening LIP 
despite antiretroviral therapy [121]. Infrequently, LIP may undergo malignant transformation 
and evolve into a pulmonary lymphoma.
Corticosteroids66
5.9. Hypersensitivity pneumonitis
Hypersensitivity pneumonitis (also known as extrinsic allergic alveolitis) refers to a group of 
diseases that develop secondary to numerous agricultural dusts, microorganisms, bioaerosols 
and/or reactive chemical species. Prompt diagnosis of hypersensitivity pneumonitis is impor-
tant as the disease is reversible in its early stages. Correct diagnosis is usually based on a com-
patible exposure history, clinical assessment, radiographic findings and response to avoidance 
of the suspected etiologic agent [122]. Acute hypersensitivity pneumonitis often occurs follow-
ing heavy exposure to an inciting agent and is usually confused with CAP. Patients present 
with fever, chest pain, cough and dyspnea about 6 hours following exposure. In most cases, 
symptoms improve within a few days after cessation of exposure to inciting agent, although 
radiographic resolution requires several weeks. Skin testing to allergens is not useful and 
serum precipitins may have a high false negative rate. Bronchoscopy with BAL shows lym-
phocytosis exceeding 20% (often >50%) and the BAL CD4+/CD8+ ratio is usually decreased 
to less than 1.0 [123]. Characteristic radiographic findings on computed tomography include 
mid-to-upper zone predominance of centrilobular ground-glass or nodular opacities with 
signs of air-trapping. Histopathological findings may reveal poorly formed granulomas and/
or a patchy mononuclear infiltration near the alveolar walls [124]. Subacute hypersensitivity 
pneumonitis presents with productive cough, dyspnea, fatigue, anorexia, and weight loss. 
Most patients have mixed obstructive and restrictive abnormalities on PFTs with a reduction 
in diffusion capacity. Radiographic findings may include diffuse micronodules, ground-glass 
opacities, or mild fibrotic changes predominantly involving the middle to upper lung zones. 
Bronchoscopy with BAL may reveal lymphocytosis and negative cultures. Lung biopsy may 
reveal poorly formed, noncaseating granulomas in the pulmonary interstitium with fibrosis and 
bronchiolitis [125]. Removal of the inciting agent results in complete resolution of findings over 
a longer period of time (weeks to months) and most patients require systemic glucocorticoid 
therapy. In the chronic progressive form of hypersensitivity pneumonitis, patients present with 
cough, dyspnea, fatigue, and weight loss. Physical examination may reveal digital clubbing and 
hypoxemia. Radiographic studies will show widespread pulmonary fibrosis; BAL may reveal 
lymphocytosis. Lung biopsy is necessary to demonstrate granulomatous pneumonitis, diffuse 
interstitial pneumonitis, bronchiolitis obliterans and distal destruction of alveoli (honey-comb-
ing) with densely fibrotic zones [126]. At this stage, removal of exposure to the inciting agent 
will only lead to partial improvement. Corticosteroid therapy (usually 0.5–1 mg/kg/day of pred-
nisone) should be prescribed to all symptomatic patients with hypersensitivity pneumonitis. 
Gradual tapering of steroid dosage can be started after 2 weeks and tapered over the ensuing 
2–4 weeks in most patients [127]. In patients with chronic hypersensitivity pneumonitis and 
extensive pulmonary fibrosis, lung transplantation may be a viable treatment option.
5.10. Idiopathic interstitial pneumonitis
IIP refer to a group of idiopathic ILDs that are characterized by infiltration of the pulmonary 
interstitium with inflammatory cells and consequently result in progressive fibrosis. IIP is a 
broad umbrella category that includes a number of different disease entities with distinct his-
tologic patterns, natural course and prognosis [128]. The American Thoracic Society (ATS) and 
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European Respiratory Society (ERS) classification [129] has recognized 6 major IIPs: (i) idiopathic 
pulmonary fibrosis (IPF); (ii) idiopathic NSIP; (iii) cryptogenic organizing pneumonitis (COP); 
(iv) respiratory bronchiolitis (RB) associated ILD; (v) acute interstitial pneumonitis (AIP); and 
(vi) desquamative interstitial pneumonitis (DIP). Two other ILDs are also included in the ATS/
ERS classification as rare IIP viz. idiopathic LIP and idiopathic pleuroparenchymal fibroelastosis 
(PPFE). A category of unclassifiable IIP is also included in the ATS/ERS classification which is 
reserved for those IIPs which do not fit the criteria for any specific category of IIP.
IPF and idiopathic NSIP are both ILDs that run a chronic course with most patients experi-
encing symptoms for many months prior to diagnosis. IPF usually presents in the sixth to 
seventh decades of life. Typical radiologic findings include bibasilar subpleural fibrosis with 
traction bronchiectasis and honeycombing in the later stages. IPF is characterized histologi-
cally by a UIP pattern with a temporal and geographical heterogeneity, patchy involvement 
of the lung parenchyma, presence of architectural distortion and fibroblast foci and absence 
of features suggesting an alternative pattern [130]. Two novel tyrosine kinase inhibitors—pir-
fenidone and nintedanib—have been approved for the treatment of IPF [131]. Despite this, the 
overall prognosis for IPF remains poor. Systemic corticosteroid therapy is often employed for 
patients who develop acute infective exacerbation of IPF, although high quality evidence in 
support of this practice is lacking [132]. Idiopathic NSIP is a distinct clinical entity and tends to 
have a subacute presentation and a better prognosis as compared to IPF. Histologically, NSIP 
is characterized by temporal and geographical homogeneity with uniform involvement of the 
lung parenchyma, mononuclear cell infiltration of the interstitium and relative preservation of 
lung architecture [133]. The term “non-specific” is used because the histologic appearance of 
NSIP lacks the characteristic features of UIP, DIP, RB-ILD or AIP. Radiologic findings include 
bibasilar subpleural reticular shadowing with traction bronchiectasis, ground-glass opacities 
and absence of honeycombing. Alternative causes of NSIP, such as collagen vascular diseases, 
drugs and infections, need to be excluded. Treatment of NSIP is with systemic corticosteroid 
therapy, usually prednisone 1 mg/kg, gradually tapered over 6–12 months [134]. Pulse-dose 
methylprednisolone therapy has also been used in those with severe disease on presentation. 
In patients who relapse or remain refractory despite systemic corticosteroid therapy, a second 
immunosuppressive agent is added to prednisone.
Cigarette smokers tend to have a number of subclinical pulmonary interstitial abnormalities 
identifiable on histopathology [135]. These subclinical abnormalities do not meet the criteria 
for any particular ILD or IIP. Smoking-related ILD include RB-ILD, DIP and Langerhans cell 
histiocytosis. Langerhans cell histiocytosis is a separate disease entity and is generally not 
included under the heading of IIP. Both DIP and RB-ILD occur in smokers, usually with a 
smoking history of over 30 pack-years, most often in the third to fourth decades of life; men 
are more commonly affected [136]. In DIP, radiologic studies reveal bilateral ground-glass 
opacities without the peripheral reticular shadowing typical of UIP. In RB-ILD, radiologic 
findings may include scattered ground-glass opacities along with bronchial wall thickening. 
Lung biopsy in DIP shows uniform histopathological findings and lacks the patchy nature typi-
cal of IPF. Honeycombing is characteristically absent and a striking feature is the presence of 
numerous “smokers’ macrophages” within the distal airspaces [137]. DIP is actually a misno-
mer as these macrophages were originally believed to be desquamated pneumocytes. A smoker 
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 macrophage is a  macrophage that contains fine brown pigment flecked with tiny blackish par-
ticles; these cytoplasmic particles stain well with Prussian blue (iron content) and periodic acid 
Schiff (polysaccharides) stains. RB-ILD has a histopathological appearance somewhat similar to 
DIP in that numerous smoker macrophages are noted; however, these pigmented macrophages 
are abundant within the lumen of respiratory bronchioles [138]. Moreover, the histopathologi-
cal findings seen in RB-ILD have a bronchiolocentric distribution, whereas DIP tends to affect the 
lung in a rather uniform and diffuse manner. The management of DIP and RB-ILD is similar; 
smoking cessation is the first line of management [139]. For patients who continue to experience 
symptoms and have worsening PFTs, systemic corticosteroid therapy is used. Rarely, other 
immunosuppressive agents may be used if patients do not improve, although evidence in this 
regard is scarce. Given the considerable overlap between RB-ILD and DIP, some researchers 
have suggested that the two categories may be merged together into a single group [140].
COP is the term applied to the idiopathic form of BOOP. This clinical disorder is characterized 
by an inflammatory pneumonitis and a proliferative bronchiolitis that results in excessive pro-
liferation of granulation tissue within the smaller airways [141]. COP often presents with an 
acute or subacute clinical picture and mimics CAP with a lack of response to antibiotics. Patients 
are most often in their fifth or sixth decades of life and both sexes are affected equally. In many 
cases, a flu-like illness may precede the onset of COP. As is the case with other IIP, secondary 
causes of organizing pneumonia (such as drugs, collagen vascular diseases and infections) 
need to be excluded. PFTs reveal a restrictive defect with impairment of gaseous exchange (dif-
fusion capacity). Radiologic studies show multiple patchy ground-glass opacities or peripheral 
consolidations [142]. Bronchoscopy with BAL is often performed to exclude other diagnoses 
such as infections, drug-induced pneumonitis, hypersensitivity pneumonitis, chronic eosino-
philic pneumonitis and malignancy. In COP itself, BAL typically reveals a “mixed pattern” 
of increased cellularity (i.e. smaller proportion of macrophages and higher proportions of 
lymphocytes, neutrophils and eosinophils). Although transbronchial lung biopsy may be per-
formed at the time of bronchoscopy, most patients suspected of having COP or other ILD 
require a thoracoscopic or open lung biopsy (i.e. via thoracotomy) to yield adequate specimens 
for histopathological evaluation [143]. Systemic corticosteroid therapy is the mainstay of treat-
ment. Prednisone 1 mg/kg/day is usually started, unless the patient has severe symptoms or 
frank respiratory failure in which cases, IV methylprednisolone 500–1000 mg/day for 5 days 
may be used initially. Patients usually respond clinically to corticosteroids within a few days to 
a few weeks. Corticosteroid therapy is generally tapered over a period of 6–12 months. Other 
immunosuppressive agents may be used in patients who have COP refractory to steroids, or 
those who relapse frequently despite moderate doses of corticosteroids [144].
AIP (also known as Hamman-Rich syndrome) has a much more aggressive and acute dis-
ease course as compared to other ILD and it is similar to acute respiratory distress syndrome 
(ARDS) in terms of its worse prognosis. In fact, AIP differs from ARDS only in that it has no 
identifiable triggering event (i.e. it is idiopathic); otherwise, the histological pattern of AIP is 
identical to that for ARDS (DAD) [145]. Clinically, it presents with acute onset of rapidly wors-
ening respiratory failure with diffuse airspace shadowing on plain radiographs. Computed 
tomography reveals bilateral diffuse ground glass opacities and/or consolidations with 
lobular sparing. The histologic hallmark of AIP is DAD as characterized by diffuse  airspace 
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 organization with or without the formation of hyaline membranes and alveolar septal thick-
ening (due to diffuse organizing fibrosis) with a geographic and temporal homogeneity [146]. 
As for other IIP, cultures should be negative and granulomas, viral inclusions or eosinophils 
should be absent on histopathology. AIP requires aggressive treatment with high doses of 
glucocorticoids—typically methylprednisolone 1–2 g/day in divided doses for 3–5 days, fol-
lowed by systemic glucocorticoid therapy for several weeks to months [147]. The mortality 
of AIP is almost 50%, and even in patients who survive the acute illness, recurrence of AIP or 
progression to a chronic ILD frequently occurs [148].
5.11. Laryngotracheitis (croup)
Laryngotracheitis (also known as croup) is a viral infection caused by parainfluenza viruses 
(most commonly, type 1) and often affects children in the first 3 years of life with a slight predis-
position for boys. Clinical symptoms include low-grade fever, dyspnea, inspiratory stridor and 
a characteristic barking cough. In older children, hoarseness may also be noticeable. In some 
cases, inflammation may extend to the lower airways and result in laryngotracheobronchitis 
or even superimposed bacterial laryngotracheobronchopneumonitis [149]. While croup is typi-
cally caused by parainfluenza viruses, other viruses may also cause croup in certain cases; these 
include respiratory syncytial virus, influenza virus, rhinoviruses and human metapneumo-
viruses [150]. Plain chest radiographs may show narrowing of the subglottic area, frequently 
referred to as the steeple sign—owing to its resemblance to the steeple of a church). It should 
be noted here that croup is different from bacterial tracheitis, acute epiglottitis and viral bron-
chiolitis. Bacterial tracheitis is a bacterial infection of the trachea that results in a thick purulent 
exudate in the trachea, frequently with involvement of the lower airways (tracheobroncho-
pneumonitis) [151]. Acute epiglottitis is an infection that was frequently caused by Haemophilus 
influenzae prior to the widespread use of the “Hib” vaccine. Most cases in vaccinated children 
and adults are caused by streptococcal or staphylococcal infections. Epiglottitis generally has a 
more rapid onset and aggressive course than croup and children tend to have high-grade fever 
and a toxic appearance [152]. Airway obstruction may be precipitated by physical examination 
or manipulative procedures, such as laryngoscopy. Viral bronchiolitis is an infection that usu-
ally occurs in infants and children below the age of 2 years. Most infections are caused by respi-
ratory syncytial virus and present with fever, cough, dyspnea and wheezing [153]. Bronchiolitis 
is treated with supportive care only and corticosteroids have no role in management.
Treatment of croup involves supportive care with humidified oxygen therapy and anti-pyret-
ics, adequate hydration, corticosteroids and nebulized epinephrine [154]. A strong body of 
evidence suggests that the use of either nebulized budesonide or single-dose dexamethasone 
provides benefits in terms of reducing length of hospital stay and decreasing visits to the 
emergency department [155]. The Westley croup score can be used to grade the severity of 
croup [156]. Patients with mild croup may be managed at home with a single dose of oral 
dexamethasone 0.6 mg/kg. Patients with moderate croup may be admitted to the hospital and 
administered an intramuscular or intravenous dose of dexamethasone along with repeated 
nebulizations of epinephrine [157]. In patients with severe croup and impending respiratory 
failure, admission to the intensive care unit may be necessary with a plan for endotracheal 
intubation in the presence of anesthesiologist and/or otorhinolaryngologist.
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5.12. Exacerbation of cystic fibrosis
CF is an autosomal recessive disorder that results from genetic mutations in the cystic fibrosis 
transmembrane conductance regular (CFTR) chloride channel. CF is the most common lethal 
genetic disorder in the European population with an incidence of about 1 in 2500 live births 
[158]. The most common genetic mutation responsible for CF worldwide is the ∆F508 mutation 
which results in deletion of a phenylalanine residue at the 508′ position of the CFTR channel. This 
mutation has a prevalence of about 70% in patients with CF. Interestingly, of the 2000 mutations 
described in CFTR, only 4 of the remaining mutations have a prevalence of greater than 1% [159]. 
In some parts of the world, mutations other than the ΔF508 mutation are relatively common; for 
instance, the G551D mutation is common in the Middle East region [160–164]. Despite the devel-
opment of novel targeted therapies for CF patients [165], the median survival for CF patients 
remains at 37 years—although it has been consistently improving over the past few decades [166]. 
In patients with CF, defective functioning of the CFTR gene results in protean manifestations, 
such as sinonasal polyposis, bronchiectasis, chronic pancreatitis with pancreatic insufficiency, 
CF-related diabetes mellitus, gut pathologies (meconium ileus, meconium ileus equivalent and 
intestinal atresia), osteoporosis, malnutrition, infertility and delayed puberty [159]. However, the 
most disabling of these manifestations is lung disease; defective mucociliary clearance leads to 
recurrent and persistent infections with virulent organisms, resulting in progressive and cumula-
tive lung damage and development of bronchiectasis and end-stage lung disease [166].
Patients with CF frequently present with recurrent and disabling infective exacerbations of their 
lung disease. The microbiologic agents implicated in pneumonia and lower respiratory tract 
infections among patients with CF are distinct from that of the general population [167–170]. 
The management of pulmonary disease in patients with CF is best carried out in dedicated CF 
centers with a multidisciplinary team that is experienced in the care of such patients [171]. In 
patients presenting with acute infective exacerbations of CF, good evidence is available to sub-
stantiate the role of antibiotics, pulmonary toilet, bronchodilators, ventilatory support and muco-
lytics [172]. The use of corticosteroids in the management of patients with CF is controversial. 
Systematic reviews of randomized controlled trials suggest that the use of inhaled or systemic 
corticosteroid on a chronic basis in patients with CF without evidence of asthma or ABPA causes 
more harm than meaningful benefits [173, 174]. However, in patients with CF who present with 
an acute infective exacerbation, some data suggest that short-term corticosteroid therapy may 
be beneficial. In a randomized controlled trial, Tepper and colleagues demonstrated that use of 
a short course of intravenous hydrocortisone in patients with acute infective exacerbation of CF 
provided a greater and sustained improvement in pulmonary function [175]. However, guide-
lines from the CF Foundation conclude that larger studies would be needed to further evaluate 
the efficacy of corticosteroids in acute exacerbations of CF vis-à-vis their safety [176].
5.13. Acute respiratory distress syndrome
ARDS is the development of acute hypoxic respiratory failure in response to an identifiable 
inciting event, which is characterized pathologically by a diffuse inflammatory process involv-
ing the lung that leads to increased vascular permeability, generalized alveolar edema, loss of 
aerated tissue and markedly decreased lung compliance [177]. ARDS can occur in response to 
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a wide range of etiologies including sepsis, acute pancreatitis, trauma, drowning, burns, aspi-
ration, transfusion-related acute lung injury, and so on; however, all these clinical entities are 
grouped together under the heading of ARDS as their clinical management is similar [178]. 
Clinically, ARDS presents with worsening hypoxemia and respiratory failure that develops 
within 24–72 hours of an inciting event. Patients typically have severe tachypnea and hypox-
emia with accessory muscle use and respiratory distress on examination; chest auscultation 
may reveal bilateral diffuse crackles. Plain radiographs reveal bilateral airspace shadowing, 
which may be patchy in the initial stages, and coalesce later to a more homogeneous pat-
tern in later stages. Arterial blood gas analysis will typically show respiratory alkalosis with 
hypoxemia and an elevated A–a gradient. The degree of hypoxemia can be quantified by the 
ratio of PaO
2
 to the fraction of inspired oxygen (FiO
2
) [179]. Computed tomography reveals 
widespread airspace opacities that may coalesce and are more prominent in the dependent 
parts of the lung. Histopathologically, the hallmark feature of ARDS is DAD (similar to AIP) 
with or without the presence of focal alveolar hemorrhage and hyaline membranes [180]. As 
per the Berlin definition, ARDS can be diagnosed if a patient has impairment in oxygenation 
(as measured by a PaO
2
/FiO
2
 ratio of ≤300 mm Hg) with bilateral airspace opacities on chest 
radiographs (not fully explained by lung collapse, pulmonary nodules or pleural effusions) 
that started within a week of a known clinical insult and are not secondary to cardiac failure 
or fluid overload as assessed by an objective assessment method (such as echocardiography) 
[181]. The PaO
2
/FiO
2
 ratio can be used to quantify the oxygenation impairment and stratify 
the severity of ARDS into severe (PaO
2
/FiO
2
 ≤ 100 mm Hg), moderate (PaO
2
/FiO
2
 101–200 mm 
Hg) or mild (PaO
2
/FiO
2
 201–300 mm Hg) [182].
Management of ARDS is centered on mechanically ventilating patients with lung protec-
tive strategies. Low tidal volume ventilation is the mainstay of management while tolerating 
permissive hypercapnia and using high PEEP to maximize alveolar recruitment and prevent 
atelectasis [183]. In patients with very severe ARDS, prone positioning techniques and extra-
corporeal membrane oxygenation may be necessary to support life [184]. The use of cortico-
steroids in patients with ARDS is controversial and remains contentious to date. There is good 
evidence to suggest that corticosteroids should not be used >14 days after onset of ARDS as 
there is no demonstrable benefit and clear evidence of harm [185]. Moreover, in patients who 
develop ARDS due to a steroid-responsive etiology, corticosteroids should be used early in the 
course of the disease [186]. In patients with severe ARDS secondary to a disease process that 
is not treated with corticosteroids, initiation of systemic corticosteroids early (<14 days) in the 
course of the disease may offer some benefit. Several meta-analyses have been published to 
evaluate the impact of steroids on mortality in ARDS and their results have been conflicting. 
Three meta-analyses suggest that there is no benefit of steroids in terms of overall mortal-
ity, but, they help to improve gas oxygenation, reduce duration of mechanical ventilation 
and decrease overall stay in the ICU [187–189]. Two other meta-analyses reported that use of 
systemic corticosteroids provided a reduction in overall mortality and reduced the duration 
of mechanical ventilation [190, 191]. In the light of such conflicting evidence, use of systemic 
corticosteroids in patients with severe ARDS remains at the discretion of the treating clinician. 
Critical care physicians should assess each case individually and decide whether to adminis-
ter corticosteroids or not based on their perceived benefits and possible adverse effects.
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5.14. Lung transplantation and transplant-related complications
Lung transplant is used as a treatment modality for a wide variety of disorders that lead to 
end-stage lung disease with the most common ones being COPD, IPF, CF, α
1
-antitrypsin defi-
ciency and idiopathic pulmonary arterial hypertension [192]. Both single-lung and double-
lung transplantation procedures are increasingly being performed; however, the availability 
of donor lungs is the main limiting factor to the number of procedures that can be performed. 
The basic selection criteria for lung transplantation include: (a) the presence of severe lung dis-
ease for which medical therapy is unavailable or ineffective and mortality without transplan-
tation is estimated to be >50% within 2 years; (b) satisfactory psychosocial support system; (c) 
likelihood to withstand lung transplant surgery is >80%; and (d) absence of other comorbidi-
ties that would limit life expectancy in the first 5 years post-transplantation [193]. Absolute 
contraindications to lung transplant include psychosocial problems or non-adherence to 
medical therapy, cigarette smoking, alcohol dependency, substance abuse, uncontrolled or 
untreatable infection, malignancy in the last 2 years, uncorrectable bleeding diathesis, sig-
nificant coronary artery disease that is not amenable to revascularization, significant dysfunc-
tion of other vital organs, severe obesity (body mass index ≥35 kg/m2), active infection with 
Mycobacterium tuberculosis, or significant deformity of the chest wall or spine that would be 
expected to cause a severe restrictive defect post-transplant [194]. Apart from these absolute 
contraindications, there are a number of other diseases or conditions that are considered rela-
tive contraindications to lung transplant. Interestingly, use of systemic corticosteroids peri-
operatively was prohibited in the past due to concerns of poor healing of the newly formed 
anastomosis [195]. However, most evidence has shown that use of prednisone in doses of up 
to 0.3 mg/kg pre-transplantation does not increase the risk of complications [196].
Corticosteroids are an important part of immunosuppressive therapy for patients undergoing 
lung transplantation. At the time of the surgical procedure, an initial dose of 500–1000 mg of 
methylprednisolone is administered intravenously as soon as the donor allograft’s vasculature 
and bronchus are anastomosed to the recipient’s respective structures, and allograft reperfu-
sion is established. Corticosteroid therapy is then continued at a dose of 0.5–1 mg/kg/day of 
prednisone (or equivalent) and gradually tapered down to a goal of 5–10 mg/day of predni-
sone (or equivalent) over a period of 6 months [197]. Depending on the transplant center’s pro-
tocols and characteristics of the recipient (age, primary lung disease, panel reactive antibodies, 
etc.), induction therapy may or may not be administered post-transplantation. For induction 
therapy, the most commonly used agents are basiliximab, alemtuzumab or anti-thymocyte 
globulin [198]. Pre-medication with acetaminophen, diphenhydramine and corticosteroids 
(methylprednisolone 125 mg IV once) is required prior to infusion of alemtuzumab or anti-
thymocyte globulin. Maintenance immunosuppression is then employed with a combination 
regimen consisting of a glucocorticoid (usually prednisone), a calcineurin inhibitor (usually 
tacrolimus or cyclosporine) and an anti-metabolite (usually mycophenolate or azathioprine) 
[199]. Occasionally, an mTOR (mechanistic target of rapamycin) inhibitor, such as sirolimus 
or everolimus, may also be used be as part of the maintenance immunosuppressive regimen; 
however, mTOR inhibitors should not be used in the first 3 months post-lung transplant as 
they may lead to fatal bronchial dehiscence [200].
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Transplant rejections represent a significant problem in the world of transplantology. 
Corticosteroid therapy forms an integral component of the management of both acute and 
chronic graft rejections. In general terms, a graft rejection is the immune response of the recip-
ient to the donor’s graft, which results in dysfunction and failure of the transplanted organ. 
From a pathological perspective, graft rejection can be cell-mediated or humoral graft rejec-
tion depending on whether cytotoxic T lymphocytes or antibodies are implicated in immuno-
pathogenesis respectively. In chronologic terms, rejection is classified into hyperacute, acute 
or chronic rejection based on temporality [201].
Hyperacute rejection occurs within 24 hours of transplantation (usually in the first few minutes 
to hours) and results in severe hypoxemia and other signs of graft failure. Such a graft rejection 
occurs due to preformed circulating antibodies in the recipient that are directed against anti-
gens of the donor. Treatment involves therapeutic plasma exchange (to remove preformed anti-
bodies), IVIG (to bind circulating antibodies & prevent them from interacting with transplanted 
tissues) and rituximab (to deplete B lymphocytes and prevent further formation of antibod-
ies) [202]. All patients who develop hyper-acute rejection are already on high-dose steroids as 
part of their usual post-transplant care. Additional therapies, such as bortezomib (proteasome 
inhibitor) or eculizumab (monoclonal antibody to C5 complement protein), are also employed 
in most cases. While the outcome of hyperacute rejection is dismal in most cases, HLA typing 
and “virtual cross-match” of donor and recipient have made it a rare occurrence [203].
Acute lung allograft rejection usually occurs within the first 6–12 months of transplantation and 
it is cell-mediated in most cases. In acute cellular lung graft rejection, treatment is with pulse-
dose methylprednisolone along with intensification of the maintenance immunosuppressive 
regimen [204]. Patients with persistent graft rejection may be treated with repeated courses of 
pulse-dose methylprednisolone along with other therapies, such as anti-thymocyte globulin, 
alemtuzumab and/or mTOR inhibitors (sirolimus or everolimus). Cases of acute humoral lung 
graft rejection developing weeks to months after transplantation are less common. Such cases 
are managed with a combination of therapeutic modalities including pulse-dose methylpred-
nisolone, therapeutic plasma exchange, IVIG, rituximab and/or intensification of maintenance 
immunosuppression [205]. Empiric antibiotics are often initiated in patients with acute lung 
graft rejection until results of microbiologic and histopathological studies are available.
Chronic lung transplant rejection remains a major source of late morbidity and mortality for 
lung transplant recipients [206]. Chronic lung allograft rejection may manifest as either bronchi-
olitis obliterans or a restrictive allograft syndrome. Bronchiolitis obliterans is the predominant 
subtype of chronic lung graft rejection and has a worse prognosis [207]. It is usually detected 
as an obstructive defect on PFTs. Histopathologically, fibrosis in the lower airways (bronchi-
oles) with formation of dense scar tissue is typical [208]. In some patients, an unexplained 
obstructive defect on PFTs is noted in the absence of definitive histopathological evidence of 
bronchiolitis obliterans; such patients are termed to have bronchiolitis obliterans syndrome. 
In restrictive allograft syndrome, patients have a demonstrable restrictive defect on PFTs 
and evidence of fibrotic changes involving the upper lung lobes [209]. In most cases, chronic 
lung allograft rejection is irreversible and most patients eventually require retransplantation 
[210]. However, several therapeutic options may be tried in such patients ( depending on the 
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transplant center’s preferences) including intensification of the immunosuppressive regimen, 
addition of azithromycin, use of montelukast, use of mTOR inhibitors, trial of anti-thymocyte 
globulin, total lymphoid irradiation or extracorporeal photophoresis [211].
6. Adverse effects
The adverse effects of corticosteroid therapy are significant and, in most circumstances, these 
effects are a compelling reason to limit the dose and/or duration of their use [18]. In many of 
the chronic diseases discussed in this chapter, toxicities of steroid therapy are a major source 
of morbidity. Additionally, most patients with such chronic diseases are often on immuno-
suppressive therapy or other toxic medications that may lead to cumulative toxicity. While 
systemic glucocorticoid therapy is associated with the most number of adverse effects, inhaled 
glucocorticoid therapy can also have some adverse effects, although they tend to be generally 
less severe [40–42]. Moreover, some of the adverse effects of corticosteroids do not manifest 
until complications develop. For instance, loss of bone mineral density may go on unchecked 
until a patient develops vertebral collapse [212]. Luckily, most of the adverse effects of ste-
roids are potentially reversible with time once corticosteroids are discontinued.
Side effects of systemic corticosteroids pertain to almost all systems of the body. Long-term 
corticosteroid therapy can cause skin thinning, dermal atrophy and purpura, especially on 
the dorsum of hand and forearm [213]. Dermal atrophy is a consequence of reduced col-
lagen synthesis due to inhibition of protein synthesis. Purpura is a combined consequence 
of dermal atrophy and increased fragility of vessels, which predisposes to bleed in response 
to minor stress. In a case–control study, Karagas and co-workers reported that the risk of 
non-melanoma skin cancer was increased among patients who used corticosteroids [214]. 
Cushingoid striae occur due to overstretching of the skin with rupture of vessels within the 
skin. Steroid-induced acne is also a well-known dermatologic adverse effect of steroids [215]. 
Ophthalmic adverse effects of corticosteroids include cataracts, increased intraocular pres-
sure and development of glaucoma [216]. Cataracts most commonly occur in a posterior 
subcapsular location and are often bilateral [41]. Central serous chorioretinopathy is another 
rare ophthalmic side effect of corticosteroids [217]. Redistribution of body fat with truncal 
obesity, buffalo hump and moon facies (Cushingoid features) develop when corticosteroids 
are used over a long period of time in high doses [218]. Prolonged periods of hyperglycemia 
predispose patients to the development of diabetes mellitus and central adiposity, which in 
turn leads to increasing insulin resistance. Insulin resistance and hyperinsulinemia lead to 
increased synthesis of very low-density lipoproteins and increase triglyceride levels and adi-
pose tissue in the body [219]. Moreover, since many pharmacologically used corticosteroids 
have weak mineralocorticoid properties, they can lead to fluid retention, hypertension, hypo-
kalemia and mild metabolic alkalosis. All these effects can culminate in accelerated athero-
sclerosis and increased incidence of cerebrovascular events and coronary artery disease [220]. 
Moreover, fluid retention and hypertension can worsen cardiac failure. Fluid retention can 
also be problematic in patients with pre-existing renal disease. In the gastrointestinal system, 
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corticosteroids can lead to a number of adverse effects including gastritis and gastrointestinal 
bleeding [221]. Corticosteroids may also impair healing of peptic ulcers and mask signs of 
gastrointestinal perforation; however, in patients taking glucocorticoids alone, routine use of 
proton pump inhibitors is not recommended [222]. Proton pump inhibitors should be given to 
patients who are taking corticosteroids along with either aspirin or other NSAIDs [223]. Fatty 
liver is another adverse consequence of prolonged corticosteroid use. In the musculoskel-
etal system, glucocorticoids lead to accelerated bone loss due to decreased osteogenesis and 
increased osteolysis [224]. Corticosteroid use can lead to osteoporotic fractures; interestingly, 
vertebral fractures have been reported in patients treated with glucocorticoids, even with a 
normal bone mineral density [225]. Avascular necrosis, especially of the head of femur, is a 
serious adverse effect of glucocorticoid therapy [226]. In children, prolonged use of corticoste-
roids can lead to slowed growth or even, permanent growth impairment [227]. Corticosteroids 
can also lead to myopathy, which manifests as proximal muscle weakness, although muscle 
enzymes (serum creatine kinase) are within normal limits [228]. With respect to the reproduc-
tive system, corticosteroid use may lead to menstrual irregularities and decreased fertility 
in both sexes [229]. Moreover, use of high doses of corticosteroids during the first trimester 
of pregnancy may elevate the risk of cleft palate slightly [230]. The risk of fetal intrauterine 
growth restriction is also elevated in women who take corticosteroids throughout pregnancy 
[231]. Corticosteroids have also been shown to have a number of adverse effects on the cen-
tral nervous system, especially when used in high doses [232]. Neuropsychiatric effects may 
include feeling of euphoria, anxiety, depression, mania, delirium or even psychosis. In a study 
by Shin et al. [233], patients with RA who were treated with oral glucocorticoids had a higher 
risk of having cognitive impairment. In another study by Keenan and colleagues [234], use 
of corticosteroids was associated with an adverse outcome on explicit memory at a period of 
1 year. Last, but not the least, the immune system is also adversely affected by glucocorticoid 
therapy and immunosuppression leads to an increased risk of infections, decreased response 
to vaccines, poor wound healing and lymphopenia [235, 236]. Neutrophilia seen with cortico-
steroid therapy is a mere consequence of demargination of the neutrophil pool.
Close monitoring of such patients for the development of adverse effects is essential [237]. 
Routine monitoring should include blood pressure charting, weight charting, regular physical 
examination, lipid profile and fasting plasma glucose. Determination of bone mineral density 
and monitoring of intraocular pressure should be considered for patients who are receiving 
high doses of corticosteroids for a prolonged duration [238]. Specifically, patients with pre-
existing co-morbid conditions, such as diabetes mellitus, hypertension, dyslipidemia, heart 
failure, peptic ulcer disease and osteoporosis, are at a much higher risk of developing adverse 
effects and must be monitored vigilantly [239].
In summary, corticosteroid therapy is a double-edged sword in patients with chronic diseases 
who are dependent on steroids. Adverse effects pertaining to nearly every system of the body 
can occur with the use of corticosteroids, which mandates that patients be treated with the 
lowest possible dose of corticosteroids for the minimum duration possible. Inhaled cortico-
steroid therapy can provide a therapeutic effect in many airway disorders, while reducing the 
risk of many steroid-induced adverse effects at the same time. Thus inhaled therapy for air-
way disorders should be preferred over systemic corticosteroid therapy, whenever possible.
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Abbreviations
A–a alveolar–arterial
ABPA allergic bronchopulmonary aspergillosis
ACE angiotensin converting enzyme
ACTH adrenocorticotrophic hormone
AIP acute interstitial pneumonitis
ALT alanine aminotransferase
ANCA antineutrophil cytoplasmic antibody
APC antigen presenting cell
ARDS acute respiratory distress syndrome
ATP adenosine 1,4,5-triphosphate
ATS American Thoracic Society
BAL bronchoalveolar lavage
BOOP bronchiolitis obliterans organizing pneumonitis
cAMP cyclic adenosine monophosphate
CAP community acquired pneumonia
CAT COPD assessment test
CF cystic fibrosis
CFTR cystic fibrosis transmembrane conductance regulator
COP cryptogenic organizing pneumonitis
COPD chronic obstructive pulmonary disease
DAD diffuse alveolar damage
DAH diffuse alveolar hemorrhage
DIP desquamative interstitial pneumonitis
DM dermatomyositis
EGPA eosinophilic granulomatosis with polyangiitis
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ERS European Respiratory Society
FEV
1
 forced expiratory volume in first second of expiration
FiO
2
 fraction of inspired oxygen
GOLD Global Initiative for Chronic Obstructive Lung Disease
GPA granulomatosis with polyangiitis
GPCR G-protein coupled receptor
GPS Goodpasture syndrome
GRE glucocorticoid-response elements
HIV human immunodeficiency virus
ICS inhaled corticosteroids
IgE immunoglobulin E
IL interleukin
ILD interstitial lung disease
IPF idiopathic pulmonary fibrosis
IVIG intravenous immunoglobulin
LABA long-acting β
2
-adrenoceptor agonist
LAMA long-acting muscarinic antagonists
LIP lymphocytic interstitial pneumonitis
mMRC modified Medical Research Council scale
MPA microscopic polyangiitis
mTOR mechanistic target of rapamycin
NFκB nuclear factor-κB
NIPPV non-invasive positive pressure ventilation
NSAID non-steroidal anti-inflammatory drug
NSIP non-specific interstitial pneumonitis
OPG osteoprotegerin
PAMPs pathogen-associated molecular patterns
PDE phosphodiesterase
PECAM-1 platelet–endothelial cell adhesion molecule-1
PFT pulmonary function test
PM polymyositis
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PPFE pleuroparenchymal fibroelastosis
PRR pattern recognition receptor
PTH parathyroid hormone
RA rheumatoid arthritis
RAAS renin–angiotensin–aldosterone system
RANK receptor activator for nuclear factor-κB
RANKL receptor activator for nuclear factor-κB ligand
RB respiratory bronchiolitis
RPC relapsing polychondritis
SABA short-acting β
2
-adrenoceptor agonist
SAMA short-acting muscarinic antagonists
SGPT serum glutamate-pyruvate transaminase
SLE systemic lupus erythematosus
SLS shrinking lung syndrome
SSc systemic sclerosis
TH1 type 1 helper T
TH2 type 2 helper T
tRNA transfer ribonucleic acid
UIP usual interstitial pneumonitis
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